#BioTechAndpharmaceuticals

Two drugmakers, Danco Laboratories and GenBioPro, had asked the Supreme Court to lift an appeals court ban on mifepristone being distributed via mail.

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.

Ultragenyx’s Rare Bootcamp gives families a roadmap to help drive research and develop new treatments for rare diseases.

From Google News - World: Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals - CNBC

Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.

All of the health-care giant's business segments, including its insurer Aetna, its retail pharmacy and health services unit, surpassed expectations.

Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.

The studies were "withdrawn because the authors drew broad conclusions that were not supported by the underlying data," the spokesperson told CNBC.

U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David Faber.

From CNBC: Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

Insurers have incomplete data on medical costs in the first quarter due to a lag in claims processing, which sets up the second quarter as the real test.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Obesity assets represent about 25% of total forecast sales of the late-stage pipeline, while oncology's share has slipped to 20%, Deloitte found.

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.

Means' nomination had stalled in the Senate over concerns about her controversial stances on vaccines, birth control, pesticides and psychedelics.

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.